Alexander A. Brescia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander A. Brescia has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alexander J. Ivacko
Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI
1 shared publication - Amanda M. Kasperek
Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI
1 shared publication - Bailey H. Brown
Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor, MI
1 shared publication - Christopher J. Varlamos
Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor, MI
1 shared publication - Claudia Schwenzer
Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor, MI
1 shared publication - Donald S. Likosky
Department of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, Michigan
1 shared publication
Latest Publications
- Open Access
- 12 November 2025
- Published by The Beryl Institute in Patient Experience Journal
- Vol. 12 (3) , 61-74
Impact of Non-Pharmacological Interventions on Patient Experience, Opioid Use, and Healthcare Utilization in Adult Cardiac Surgery: A Randomized Controlled Mixed Methods Trial
Non-pharmacological techniques designed to reduce anxiety, pain, and healthcare utilization have shown effectiveness in pediatric and non-surgical adult populations; however, their application has not been widely evaluated among adult surgical patients. This study randomized opioid-naive adults undergoing first-time, elective cardiac surgery to receive either targeted interventions from a trained “comfort coach” or usual care. The primary outcome assessed was healthcare utilization, specifically measured as the number of days at home within the first 30 days post-surgery. Secondary outcomes included postoperative opioid use and patient-reported outcomes, collected via validated surveys. Additionally, 50 participants in the intervention group completed semi-structured qualitative interviews to explore their experience and acceptability of the intervention. Among the 160 randomized subjects (COACH: n = 77; USUAL CARE: n = 79), three did not undergo surgery and one was excluded for dementia, leaving 156 participants with a mean age of 63 years, 33% of whom were female. The primary outcome was not statistically different between groups, with the COACH group averaging 22.8 ± 4.4 days at home and the USUAL CARE group 22.0 ± 4.5 days (p = 0.26). Both groups exhibited similar decreases in anxiety and depression from preoperative clinic to 90-days postoperatively, and discharge pain scores averaged below 3/10. Notably, opioid prescriptions were larger than patient-reported consumption (p < 0.001). Qualitative analysis revealed the comfort coach intervention was highly valued, with participants identifying positive themes regarding the role and impact of the coach. These findings suggest that a comfort coach is a valued, novel healthcare role for cardiac surgery patients, and further research should prioritize comprehensive patient-reported outcomes.
- 12 November 2025
- Published by The Beryl Institute in Patient Experience Journal
- Vol. 12 (3) , 61-74
Open AccessImpact of Non-Pharmacological Interventions on Patient Experience, Opioid Use, and Healthcare Utilization in Adult Cardiac Surgery: A Randomized Controlled Mixed Methods Trial
Non-pharmacological techniques designed to reduce anxiety, pain, and healthcare utilization have shown effectiveness in pediatric and non-surgical adult populations; however, their application has not been widely evaluated among adult surgical patients. This study randomized opioid-naive adults undergoing first-time, elective cardiac surgery to receive either targeted interventions from a trained “comfort coach” or usual care. The primary outcome assessed was healthcare utilization, specifically measured as the number of days at home within the first 30 days post-surgery. Secondary outcomes included postoperative opioid use and patient-reported outcomes, collected via validated surveys. Additionally, 50 participants in the intervention group completed semi-structured qualitative interviews to explore their experience and acceptability of the intervention. Among the 160 randomized subjects (COACH: n = 77; USUAL CARE: n = 79), three did not undergo surgery and one was excluded for dementia, leaving 156 participants with a mean age of 63 years, 33% of whom were female. The primary outcome was not statistically different between groups, with the COACH group averaging 22.8 ± 4.4 days at home and the USUAL CARE group 22.0 ± 4.5 days (p = 0.26). Both groups exhibited similar decreases in anxiety and depression from preoperative clinic to 90-days postoperatively, and discharge pain scores averaged below 3/10. Notably, opioid prescriptions were larger than patient-reported consumption (p < 0.001). Qualitative analysis revealed the comfort coach intervention was highly valued, with participants identifying positive themes regarding the role and impact of the coach. These findings suggest that a comfort coach is a valued, novel healthcare role for cardiac surgery patients, and further research should prioritize comprehensive patient-reported outcomes.
- 1 December 2024
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 41 (06) , 595-600
Update on Existing and Upcoming Branched and Fenestrated Thoracic Aortic Arch Stent Grafts
Conventional management of thoracic aortic arch aneurysm and dissection with aneurysmal degeneration remains open surgical repair. However, multiple branched and fenestrated endograft systems offer promise for hybrid or total endovascular treatment of aortic arch pathology. Two zone 0 solutions involving an aortic arch with innominate branch and ascending aorta components are contemporarily in trial: the Gore thoracic branch endoprosthesis and ascending stent graft in the ARISE II Trial (W. L. Gore & Associates, Newark, Delaware) and the NEXUS Arch Stent Graft System (Endospan Ltd., Herzliya, Israel). Both device systems require a debranching procedure prior to endovascular treatment. Patients deemed appropriate for endovascular treatment with acute pathology or not qualifying for one of these trial devices may undergo homemade single or multiple fenestrated physician-modified endovascular grafts or in situ laser fenestration of aortic arch grafts with branch stenting to treat arch pathology. Ultimately, a durable total endovascular solution must achieve comparable or superior outcomes compared with open surgical repair, at significantly lower impact to patients. Branched and fenestrated endovascular treatments for aortic arch pathology require further investigation and follow-up to determine early, mid, and long-term outcomes including mortality, stroke, and endoleak requiring reintervention. * J.W.O. and P.K. contributed equally and are co-senior authors. Article published online: 04 April 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 December 2024
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 41 (06) , 595-600
Update on Existing and Upcoming Branched and Fenestrated Thoracic Aortic Arch Stent Grafts
Conventional management of thoracic aortic arch aneurysm and dissection with aneurysmal degeneration remains open surgical repair. However, multiple branched and fenestrated endograft systems offer promise for hybrid or total endovascular treatment of aortic arch pathology. Two zone 0 solutions involving an aortic arch with innominate branch and ascending aorta components are contemporarily in trial: the Gore thoracic branch endoprosthesis and ascending stent graft in the ARISE II Trial (W. L. Gore & Associates, Newark, Delaware) and the NEXUS Arch Stent Graft System (Endospan Ltd., Herzliya, Israel). Both device systems require a debranching procedure prior to endovascular treatment. Patients deemed appropriate for endovascular treatment with acute pathology or not qualifying for one of these trial devices may undergo homemade single or multiple fenestrated physician-modified endovascular grafts or in situ laser fenestration of aortic arch grafts with branch stenting to treat arch pathology. Ultimately, a durable total endovascular solution must achieve comparable or superior outcomes compared with open surgical repair, at significantly lower impact to patients. Branched and fenestrated endovascular treatments for aortic arch pathology require further investigation and follow-up to determine early, mid, and long-term outcomes including mortality, stroke, and endoleak requiring reintervention. * J.W.O. and P.K. contributed equally and are co-senior authors. Article published online: 04 April 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA